Introduction
============

Esophageal cancer is one of the most common malignant neoplasms worldwide, ranking seventh in incidence and sixth in mortality among tumors of all sites in both males and females combined, according to the recent statistics of the World Health Organization (WHO) 2012 (<http://globocan.iarc.fr>/). The two main histological esophageal cancer types, adenocarcinoma (ADC) and squamous cell carcinoma (SCC) differ in their incidence, geographic distribution, ethnic pattern, and etiology. Esophageal squamous cell carcinoma (ESCC) is the most prevalent type and constitutes more than 90% of esophageal cancers worldwide,[@B1] even though esophageal ADCs are more prevalent in the USA.[@B2] Regions with such high incidence of ESCC (15150/100,000) are referred to as the famous \'\'Asian Esophageal Cancer Belt,\'\' which includes the countries of the Caspian littoral region, the central Asian republics, Mongolia and north-western China, which have a 10-100 fold greater chance of being affected by esophageal cancer compared to other countries.[@B3] The Jilin Province in North-Eastern China is part of the "Asian Esophageal Cancer Belt." The major ethnic groups in the Jilin Province comprise the Han Chinese (\~91%), Korean (\~ 4.3%), and Manchu (\~ 3.4%) populations.

Multiple etiologies including several behavioral and environmental factors such as an individual\'s diet, tobacco smoking, alcohol consumption, exposure to chemical carcinogens, and chronic inflammation are known to be risk factors for the development of ESCC.[@B4] Regardless of the ethnic origin of the patients and the etiological factors, genetic instabilities such as microsatellite instability and chromosomal instability are associated with tumorigenesis of ESCC. Chromosomal instabilities are commonly a consequence of chromosomal or chromosome segment abnormalities resulting in DNA copy number changes (CNCs) that occur during in tumor progression. Analysis of the DNA CNC anatomy showed that human cancers can be classified by DNA CNC profiling, because it is non-randomly selected according to the biological backgrounds of the cancer.[@B5] These CNCs may lead to loss of function in tumor suppressor genes and/or gain of function in oncogenes. Interestingly, high level DNA CNCs (amplification) in tumors are frequently restricted to certain chromosomal regions that contain well-known oncogenes, which are also overexpressed or activated.[@B6],[@B7] Some oncogenes, such as *NMYC, LMYC* and *GLI*, were originally discovered because of their genomic amplification in human tumors.[@B7] Therefore, the detection and discovery of unidentified or incompletely described CNCs and the relevant genes located within these CNCs can lead to identification of genes putatively involved in growth control and tumorigenesis.

The recently available whole genomic array comparative genomic hybridization (CGH), a high-throughput genomic technology, facilitates the accumulation of high resolution data of the genomic imbalances associated with disease. In this study, we were able to define the regions of gains/amplification and losses in ESCC, and through integration of copy number, we identified the possible candidate target genes that could give insights into the pathology and molecular mechanisms of ESCC. It may therefore provide information relevant to early tumor detection, refined prognosis, and the development of novel targeted therapeutics.

Materials and Methods
=====================

Tumor Samples
-------------

The study included samples from 19 advanced ESCC cases from the Jilin Province in the north-east part of the China, diagnosed according to the WHO classification.[@B8] The clinical characteristics and risk factors of these samples are summarized in Table [1](#T1){ref-type="table"}. Of the 19 cases studied, 18 were from male patients and only one was from a female patient. The mean age of the patients was 57 (range: 37-76) years. The stage of each tumor was classified according to the tumor, node, and metastasis (TNM) classification of the International Union against Cancer[@B9] and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (<http://www.nccn.org/professionals/physician_gls/f_guidelines.asp>) as follows: stage I, two cases; stage II, six cases; stage III, eight cases; information for three cases was not available. The histopathological grades of the samples were as follows: grade 1 (well differentiated/low grade squamous cell carcinoma), one case; grade 2 (moderately differentiated/intermediate grade squamous cell carcinoma), eighteen cases; and grade 3 (poorly differentiated/high grade squamous cell carcinoma), none. All patients had negative histories of exposure to either chemotherapy or radiotherapy before surgery, and were not diagnosed with other cancers. Two of the patients had a family history of esophageal cancer. Unfortunately, the information of postsurgical pathological stages was not available. Informed consent was obtained from the enrolled patients with the approval of the ethics committee of the First Hospital of Jilin University (IRB\#2011-002). Tumor samples were obtained surgically in the Department of thoracic surgery, at the First Teaching Hospital of Jilin University. Histologically normal esophageal mucosa was surgically removed from the primary tumor regions by experienced pathologists and the primary tumor samples were snap-frozen and stored at -80°C. DNA was isolated from the samples by proteinase K digestion followed by phenol-chloroform extraction according to standard protocols.

Array CGH assay
---------------

Array CGH was performed according to the manufacturer\'s protocol with minor modifications on a 385k oligonucelotide chip (Roche/NimbleGen System Inc., Madison, WI). Commercially available pooled normal control DNA was used (Promega Corporation, Madison, WI) as the reference. The patients DNA and the reference DNA were labeled with either Cyanine 3 (Cy-3) or Cyanine 5 (Cy-5) by random priming (Trilink Biotechnologies, San Diego, CA) and were then hybridized to the chip via incubation in the MAUI hybridization system (BioMicro Systems, Salt Lake City, UT). After 18-hours of hybridization at 42°C, the slides were washed and scanned using an MS200 system (Roche/NimbleGen System Inc., Madison, WI). Profile smoothing and breakpoint detection was performed with NimbleScan version 2.4 and SignalMap version 1.9 (NimbleGen System Inc., Madison, WI). If a smoothed copy number log2 ratio was found to be above 0.15 or below -0.15 across five neighboring probes, it was defined as a gain or a loss, respectively. Amplifications were defined as those with a smoothed DNA copy number ratio of above 0.5 and homozygous deletions were defined as those with a smoothed DNA copy number ratio of below -0.4.

Immunohistochemistry (IHC) staining for *CTTN* (cortactin) and *CCND1* (cyclin D1)
----------------------------------------------------------------------------------

IHC studies were performed on formalin-fixed, paraffin embedded (FFPE) slides of ESCC tumor tissues to explore the expression of *CTTN* and *CCND1* according to the manufacturer\'s protocol using rabbit monoclonal antibodies against *CTTN* and *CCND1* and horseradish peroxidase (HRP) labeled Goat anti-rabbit polyclonal secondary antibody (Abcam plc, Cambridge, MA). Counterstaining was carried out with hematoxylin. The expression score was determined by assessing staining intensity and the percentage of immunoreactive cells.

Results
=======

Overview of Genomic Imbalance Profiling of 19 ESCCs
---------------------------------------------------

An overview of genomic imbalance profiling in 19 ESCC cases is shown in Fig [1](#F1){ref-type="fig"}. Genomic CNCs (gains, losses, amplification and homozygous deletion) were discovered all 19 cases by using array CGH. Net gains (13 cases) of genetic material were more frequent than net losses (6 cases). The sizes of net genomic imbalances per case ranged from a loss of 663.4 Mb (\~ 22 % of genome) to a gain of 694.4Mb (\~ 2% of genome) (Table [1](#T1){ref-type="table"} and Fig [S1](#SM1){ref-type="supplementary-material"}). The mean number of gains per case was \~ 15, ranging from 3 to 31, and the mean number of losses per case was \~ 11, ranging from 0 to 21. The gain sizes ranged from 31.3 kb (TL0123) to 242.7 Mb (TL0123), and the loss sizes ranged from 56.2 kb (TL0124) to 225.7 Mb (TL0127). Approximately 8.6 % (46/537) of the total genomic imbalances were smaller than 1 Mb; from this subset, 58.7 % (27/46) of the total imbalances were gains and 41.3 % (19/46) were losses. The most frequent genomic imbalances detected in more than 8 out of 19 ESCC cases (\> 42%) were gains of 1q21.1-qter, 3q13.11-qter, 5pter-p11, 7pter-p15.3, 7p12.1-p11.2, 7q11-q11.2, 8p12-qter, 11q13.2-q13.3, 12pter-p13.3, 17q24.2, 20q11.21-qter, and 22q11.21-q11.22; and losses of 3pter-p11.1, 4pter-p12, 4q28.3-q31.22, 4q31.3-q32.1, 9pter-p12, 11q22.3-qter, and 13q12.11-q22.1 (Table [2](#T2){ref-type="table"}).

The amplifications, which showed high-level copy number gains defined as log2 ratios of more than 0.5, were observed in 41 segmental chromosome regions and are summarized in Table [S1](#SM1){ref-type="supplementary-material"}. Of these, the 7p11.2 region was amplified in 3 cases and gained in 7 cases and the region of 11q13.3 was amplified in 10 cases and gained in 4 cases and was the most prominent feature in our sample set. Amplification of 7p11.2 was separated by two regions. The size of the smallest region of overlap (SRO) of distal 7p11.2 is estimated to be \~ 631.0 kb and includes the *EGFR*gene. The size of the SRO of proximal 7p11.2 is estimated to be \~1.4 Mb and includes nine genes, which are *ZNF713, MRPS17, GBAS, PSPH, SUMF2, PHKG1, CHCHD2, CCT6A,*and*LOC389493*. The SRO of the 11q13.3 amplification is estimated to be \~ 406.4 kb in size, and includes *PPFIA1, CTTN*, and*SHANK2* (Fig [2](#F2){ref-type="fig"}A).

Two interesting possible homozygous losses with a log2 ratio less than -0.4, that are smaller than 1 Mb were identified (Table [S2](#SM1){ref-type="supplementary-material"}). These loci harbored putative tumor suppressor genes (TSGs) including*FHIT*and *CDKN2*.

Overexpression of *CTTN* (cortactin) and *CCND1* (cyclin D1) on 11q13
---------------------------------------------------------------------

IHC staining was performed using antibodies against proteins cortactin and cyclin D1 which are encoded by *CTTN*and *CCND1*, respectively, on FFPE tissue slides of ESCC as well as of normal esophageal epithelia (Fig [2](#F2){ref-type="fig"}B and Table [3](#T3){ref-type="table"}). The correlation of genomic copy number gain/amplification and protein expression of *CTTN*and*CCND1* genes is summarized in table [3](#T3){ref-type="table"}. All 17 cases, that were available for performing IHC studies, exhibited strong *CTTN* positive staining. The consistency of the genomic CNCs with the protein expression level of*CTTN* was 76.5% (13/17). Positive staining of *CCND1* was observed in eight out of ten cases tested, including one case without genomic copy number gain or amplification, and the consistency of genomic CNC with protein expression levels of *CCND1* was found to be 70% (7/10) in the ESCC cases. The normal epithelia of the esophagus showed negative immunoreactions for both *CTTN* and *CCND1*.

Discussion
==========

We investigated genomic CNCs in 19 ESCC cases by whole genomic array CGH. It was recognized that total number of gains/amplifications (280) was 1.3 times more frequent than the total number of losses (211). Of 19 cases with genomic imbalances, 13 cases had net-genomic gain (24.1 - 694.4 Mb) and 6 cases had net-genomic loss (79.1 - 663.4 Mb), indicating that net genomic gains are more common than losses. The most frequent genomic imbalances detected in our samples were gains of 1q21.3-qter (8/19), 3q13.11-qter (8/19), 5pter-p11 (10/19), 7pter-p15.3 (9/19), 7p12.1-p11.2 (9/19), 7q11-q11.2 (8/19), 8p12-qter (9/19), 11q13.2-q13.3 (14/19), 12pter-p13.31 (9/19), 17q24.2 (8/19), 20q11.21-qter (11/19), and 22q11.21-q11.22 (9/19); and losses of 3pter-p11.1 (12/19), 4pter-p12 (8/19), 4q28.3-q31.22 (8/19), 4q31.3-q32.1 (8/19), 9pter-p12 (8/19), 11q22.3-qter (9/19), and 13q12.11-q22.1 (8/19) (Table [2](#T2){ref-type="table"}). These findings are compatible with previous findings by other groups.[@B10]-[@B12] Moreover, gains of 3q, 8q23-qter, 11q13.2, and 20q and loss of 7q34, 11q22-qter, and 18q21.1-q23 have been positively associated with poor outcome in ESCCs.[@B13]-[@B16]

Interestingly, the reciprocal loss of 3p and gain of 3q was observed in 8 of 19 cases in our study. The reciprocal loss of 3p and gain of 3q is a frequent phenomenon in various epithelial tumors. Especially, the isochromosome 3q was visualized in lung cancer, squamous cell carcinomas of the vulva, oral, and the head and neck, as well as in the ESCC cell line KYSE 410-4,[@B17]-[@B21], suggesting that isochromosome 3q formation is a mechanism of somatic chromosomal aberrations, resulting in reciprocal loss of 3p and gain of 3q during epithelial cell carcinogenesis.

Amplifications were observed in 41 segmental regions, of which 7p11.2 and 11q13.3 were the most repeatedly involved interesting regions (Table [S1](#SM1){ref-type="supplementary-material"}). Amplification of 11q13.3 was the most prominent finding in our study. A total of 14 cases out of 19 showed copy number gain of 11q13.3. Of these 14 cases with gains, 10 cases showed amplification of different sizes ranging from 406.4 kb to 5.9 Mb (Fig [2](#F2){ref-type="fig"}A). The various sizes of the 11q13 amplification containing various oncogenes is one of the most frequent amplification events, which is observed in 28-70 % of ESCC cases [@B22]-[@B24] and a significant positive correlation between copy number gain and mRNA expression levels has been reported in this region.[@B13] Previous studies have especially proposed the important role of *CCND1* and *CTTN* in ESCC.[@B25],[@B26] Regarding the collaborative function of these two genes, it can be hypothesized that overexpression of *CCND1* results in cell proliferation along with overexpression of *CTTN*, and may facilitate invasive and metastatic behavior in tumor cells. In the present study, subsequent examination of *CCND1* and *CTTN* protein expression levels confirmed that genomic amplification status parallels the increased protein level. Moreover, *CTTN* amplification is likely the most prominent mechanism of cortactin overexpression encoded by *CTTN*. Since five cases without genomic amplification also showed high levels of *CTTN*protein expression, mechanisms other than genomic amplification, such as the CALR-STAT3-CTTN-Akt pathway may also be involved in the upregulation of *CTTN* expression.[@B27] It is unfortunate that we were not able to evaluate the statistical significance of the relationship between the amplification/overexpression level of *CCND1*/*CTTN*and clinicopathological characteristics such as Tumor, Node, Metastasis (TNM) stage due to limitation of case number and the late stage of cancer in the patient. However, this can be supported by a previous study showing that overexpression of *CTTN* in ESCC was significantly associated with poor prognosis in patients,[@B28] suggesting the possibility of *CTTN* as a valuable marker of ESCC.

Amplification of 7p11.2 harbored an oncogene *EGFR*, which is one of the tyrosine kinase receptors that is broadly distributed in the human epithelial cell membrane. Amplification and overexpression of *EGFR* has been reported in ESCC and was significantly associated with a poor prognosis in ESCC patients indicating that it may play an important role in ESCC progression.[@B29],[@B30]

The possible homozygous losses smaller than 1 Mb that encompass interesting putative tumor suppressor genes (TSG), such as *FHIT*and *CDKN2A*were identified (Supplementary Table [2](#SM1){ref-type="supplementary-material"}). Additional sequencing analysis of *CDK2NA* revealed a somatic mutation in exon 2 (c.31_32dupCC;p.S12Lfs\*15) leading to a stop codon, in one tumor case (TL 0122) of 19 (Fig [S2](#SM1){ref-type="supplementary-material"}) without the mutation in adjacent normal tissues. *FHIT* and *CDKN2A*are virtually known as the most frequently affected genes after *TP53* in the context of homozygous deletion, promoter hypermethylation, loss of heterozygosity (LOH), and point mutations in various human cancers including ESCC.[@B31]-[@B36]

Conclusion
==========

Our study further evidences the important role of *CTTN* and *CCDN1* in 11q13 amplification/expression and the losses of TSGs, such as *CDKN2A* and *FHIT*, in advanced stages of ESCC. In future studies, a larger sample size and more early-stage samples are needed to obtain more statistically reliable data and to verify valuable markers for the early detection and targeted therapy of ESCC.

Supplementary Material {#SM0}
======================

###### 

**Supplementary Methods. Table S1** High copy number amplification/gain segments and genes and ESCC samples.**Table S2** Possible homozygous loss that is smaller than 1.0 Mb. **Figure S1**. Net genomic imbalances in 19 ESCC samples. **Figure S2** A somatic mutation in exon2 of *CDKN2A*c.331_32dupCC (p.S12Lfs\*15) was detected in one ESCC tumor tissue (red box) but not in the adjacent normal tissue.

###### 

Click here for additional data file.
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![Summary of the array-CGH results from 19 cases of ESCC samples. Gains of DNA are demonstrated as green vertical lines to the right of the chromosome idiograms. Losses of DNA are demonstratedas red vertical lines to the left of the chromosome idiograms.](ijmsv13p0868g001){#F1}

![(A) Amplification of 11q13.2-q13.3 as detected by the array CGH (log2\>0.5). The X-axis indicates genomic location and the Y-axis indicates log2 ratio. SRO: smallest region of overlap. (B) Representative IHC images of *CCND1* (cyclin D1) and *CTTN* (cortactin) in ESCC (case TL0134). Tumor cells showed strongly positive nuclear staining of *CCND1* and cytoplasmic *CTTN* compared to adjacent normal cells which are negative for *CCND1* and *CTTN*. Original magnification, ×200 (large image) and ×400 (small image).](ijmsv13p0868g002){#F2}

###### 

Clinical characteristics and risk factors of 19 ESCC samples

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   ID       Age(y)/sex   TNM stage   Stage   Histology grade   Tumor location   Smoking (Y/N)   Drinking\   Family history of cancer   Genomic size of total gain, Mb   Genomic size of total loss, Mb   Net imbalances, Mb (%)
                                                                                                     (Y/N)                                                                                                    
  ----- -------- ------------ ----------- ------- ----------------- ---------------- --------------- ----------- -------------------------- -------------------------------- -------------------------------- ------------------------
  1     33T      72/M         T2N1M0      IIB     Moderate          lower            N               N           N                          302.7                            181.4                            +121.3 (4.0)

  2     39T      58/M         T3N2M0      IIIB    Moderate          lower            Y               Y           N                          136.1                            0                                +136.1 (4.5)

  3     44T      60/M         T3NXM0      N/A     Moderate          lower            Y               Y           N                          668.9                            831.6                            -162.7(5.4)

  4     57T      50/M         T3N2M0      IIIB    Moderate          lower            Y               Y           Y                          267.9                            108.1                            +159.8 (5.3)

  5     61T      76/F         T3N3M0      IIIC    Moderate          lower            Y               N           N                          119.6                            352.4                            -232.8 (7.8)

  6     74T      47/M         T3N3M0      IIIC    Moderate          lower            Y               Y           N                          536                              48.3                             +487.7 (16.3)

  7     79T      40/M         T3N0M0      IIA     Moderate          lower            Y               Y           N                          232.7                            896.1                            -663.4 (22.1)

  8     80T      67/M         T3N1M0      IIIA    Moderate          lower            Y               Y           N                          830.5                            806.4                            +24.1 (0.8)

  9     97T      46/M         T3N0M0      IIA     Moderate          lower            Y               Y           N                          238.4                            29.6                             +208.8 (7.0)

  10    TL0140   44/M         T1N0M0      IB      Moderate          upper            N               N           Y (EC)                     525.6                            604.6                            -79 (2.6)

  11    TL0134   48/M         T3N1M0      IIIA    Moderate          lower            Y               Y           Y                          454.8                            375.7                            +79.1 (2.6)

  12    TL0129   55/M         T3N0M0      IIB     Moderate          upper            Y               Y           N                          549.2                            460.9                            +88.3 (2.9)

  13    TL0128   72/M         T2NXM0      N/A     Well              lower            Y               Y           Y (EC)                     1090.6                           1298.7                           -208.1 (6.9)

  14    TL0127   65/M         T3N1M0      IIIA    Moderate          middle           Y               Y           N                          911.1                            410.9                            +500.2 (16.7)

  15    TL0124   61/M         T1N0M0      IB      Moderate          lower            N               Y           N                          787.2                            752.5                            +34.7 (1.2)

  16    TL0122   60/M         T1N1M0      IIB     Moderate          lower            Y               Y           N/A                        756.7                            62.3                             +694.4 (23.1)

  17    TL0123   52/M         T2N0M0      IIB     Moderate          upper            Y               Y           N                          1022.2                           414.2                            +608 (20.3)

  18    TL0110   37/M         T3N1M0      IIIA    Moderate          lower            Y               Y           N                          801.3                            598.7                            +202.6 (6.8)

  19    TL0105   66/M         T2NXM0      N/A     Moderate          lower            Y               Y           N                          394.3                            787.4                            -393.1 (13.1)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: N/A, not available; TNM, tumor, node, metastasis; Y/N, yes/no

###### 

Frequently alternated loci and interesting genes in ESCC samples

  ---------------------------------------------------------------------------------------------------------------------------------------------
           Chromosome        Genomic coordinates\      Frequency   Selected interesting gene (s)
                             (NCBI Build 36.3) (bp)                
  -------- ----------------- ------------------------- ----------- ----------------------------------------------------------------------------
  Gains    1q21.3-qter       153,250,154-246,756,433   8/19        *OBSCN, PTPRC, KCNK2, RGS1, KCNH1, S100A3, ENAH*

           3q13.11-qter      104,562,526-199,325,140   8/19        *TNK2, TNFSF10, FGF12*

           5pter-p11         68,753-45,806,337         10/19       *SLC1A3, TRIO, RNASEN,TERT, IRX1, FGF10*

           7pter-p15.3       137,567-23,662,661        9/19        *TWIST1, MAD1L1, NUDT1*

           7p12.1-p11.2      51,937,714-56,087,631     9/19        *SEC61G, EGFR, ECOP, PSPH*

           7q11-q11.2        61,093,897-66,168,768     8/19        *ZNF107, ZNF92, GUSB, RABGEF1*

           8p12-qter         37,175,015-14,6262,725    9/19        *MYC, WISP1, FOXH1*

           11q13.2-q13.3     68,687,593-70,681,358     14/19       *MYEOV, CCND1,ORAOV1, FGF19, FGF4, FGF3, ANO1, FADD, PPFIA1, CTTN, SHANK2*

           12pter-p13.31     18,891-8,250,087          9/19        *CCND2, FGF23, TNFRSF1A, LTBR, GRIN2B*

           17q24.2           61,843,907-63,875,054     8/19        *BPTF, KPNA2*

           20q11.21-qter     29,275,015-62,387,649     11/19       *E2F1, AURKA*

           22q11.21-q11.22   18,756,412-21,706,352     9/19        *CRKL, UBE2L3, MAPK1, PPM1F*

  Losses   3pter-p11.1       37,570-90,393,787         12/19       *FANCD2, CTNNB1, WNT7A, FBLN2, TGFBR, FHIT*

           4pter-p12         191-48,150,025            8/19        *UCHL1*

           4q28.3-q31.22     135,093,980-145,125,004   8/19        *SETD7*

           4q31.3-q32.1      152,306,484-158,362,524   8/19        *FBXW7*

           9pter-p12         81,476-42,344,999         8/19        *MTAP, CDKN2A, CDKN2B, PCSK5*

           11q22.3-qter      102,643,870-134,450,069   9/19        *ATM*

           13q12.11-q22.1    20,975,030-72,617,826     8/19        *CDK8, BRCA2, STARD13, ATP7B*
  ---------------------------------------------------------------------------------------------------------------------------------------------

###### 

Copy number variation and protein expression of *CCND1* and*CTTN*in ESCC samples

  Case ID   CCND1           CTTN                                
  --------- --------------- ------------------- --------------- -------------------
  33T       Amplification   Strongly positive   Amplification   Strongly positive
  39T       Gain            Positive            Gain            Strongly positive
  44T       Normal          Negative            Normal          Strongly positive
  57T       Gain            Strongly positive   Gain            Strongly positive
  61T       Normal          Positive            Normal          Strongly positive
  74T       Amplification   Strongly positive   Amplification   Strongly positive
  79T       Amplification   NA                  Amplification   Strongly positive
  80T       Amplification   Strongly positive   Amplification   Strongly positive
  97T       Gain            Negative            Gain            Strongly positive
  TL0105    Normal          N/A                 Normal          Strongly positive
  TL0110    Normal          N/A                 Normal          N/A
  TL0122    Gain            N/A                 Gain            Strongly positive
  TL0123    Amplification   N/A                 Amplification   N/A
  TL0124    Amplification   N/A                 Amplification   Strongly positive
  TL0127    Amplification   N/A                 Amplification   Strongly positive
  TL0128    Amplification   N/A                 Amplification   Strongly positive
  TL0129    Normal          N/A                 Normal          Strongly positive
  TL0134    Amplification   Strongly positive   Amplification   Strongly positive
  TL0140    Gain            Strongly positive   Amplification   Strongly positive

Abbreviations: N/A: not available
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